Results of a planned interim toxicity analysis with trimodality therapy, including carboplatin AUC = 4, paclitaxel, 5-fluorouracil, amifostine, and radiation for locally advanced esophageal cancer: Preliminary analyses and treatment recommendations from the North Central Cancer Treatment Group

International Seminars in Surgical Oncology

Volumn 1, Issue , 2004, Pages

  Jatoi, Aminah ^a   Martenson, James ^a   Mahoney, Michelle R ^a   Lair, Bradley S ^b   Brindle, Jeffrey S ^c   Nichols, Frank ^a   Caron, Normand ^d   Rowland, Kendrith ^e   Tschetter, Loren ^f   Alberts, Steven ^a  

^a MAYO CLINIC   (United States)

^b Iowa Oncology Research Association Community Clinical Oncology Program   (United States)

^c ALTRU HEALTH SYSTEM   (United States)

^d Toledo Community Hospital   (United States)

^e Sioux Community Cancer Consortium   (United States)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; CARBOPLATIN; FLUOROURACIL; PACLITAXEL;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DEHYDRATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DYSPHAGIA; DYSPNEA; ELECTROLYTE DISTURBANCE; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HUMAN; HYPOTENSION; INFECTION; LEUKOPENIA; MALE; MELENA; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; NAUSEA; NEUROPATHY; NEUTROPENIA; PAIN; PHASE 2 CLINICAL TRIAL; SYNCOPE; THROMBOPHLEBITIS; TOXICITY TESTING; VOMITING;

EID: 18244409873     PISSN: 14777800     EISSN: None     Source Type: Journal    
DOI: 10.1186/1477-7800-1-9     Document Type: Article

References (9)

1. Walsh TN, Noonan N, Hollywood D, et al.: A comparison of multimodality therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996, 335:462-7.
2. Urba S: Combined modality therapy of esophageal cancer - standard of care? Surg Oncol Clin N Am 2002, 11:377-86.
3. Meluch AA, Hainsworth JD, Gray JR, et al.: Preoperative combined modality therapy with paclitaxel, carboplatin, prolonged infusion 5-fluorouracil, and radiation therapy in localized esophageal cancer: preliminary results of a Minnie Pearl Cancer Research Network phase II trial. Cancer J Sci Am 1999, 5:84-91.
4. Kleinberg L, Knisely JPS, Heitmiller R, et al.: Mature survival results with preoperativ cisplain, protracted infusional 5-fluorouracil, and 44 Gy radiotherapy for esophageal cancer. Int J Radiation Oncol Biol Phys 2003, 56:328-334.
5. Meluch AA, Greco FA, Burris JR, et al.: Preoperative paclitaxel, carboplatin, 5-FU and radiation therapy for localized esophageal cancer: final results of a Minnie Pearl Cancer Research Network phase II trial. Proceedings of the American Society of Clinical Oncology 2001:636A.
6. Zemanova M, Pazdro A, Novak F, et al.: Neoadjuvant chemotherapy with paclitaxel, carboplatin, 5-fluorouracil with consecutive surgery in esophageal cancer. Annals of Oncology 2002, 13(Suppl 5):188.
7. Koukourakis MI, Kyrias G, Kakolyris S, et al.: Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study. J Clin Oncol 2000, 18:2226-2233.
8. Anne PR, Curran WJ: A phase II trial of subcutaneous amifostine and radiation therapy in patients with head and neck cancer. Semin Radiat Oncol 2002, 12(Suppl 1):18-19.
9. Therasse P, Arbuck SG, Eisenhauer EA, et al.: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-16.